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zinc transporter expression in 
human patients with autism related 
mutations in SHANK3
Stefanie Pfaender1, Ann Katrin Sauer2, Simone Hagmeyer2, Katharina Mangus2, 
Leonhard Linta3, Stefan Liebau3, Juergen Bockmann1, Guillaume Huguet4,5,6, Thomas Bourge
ron4,5,6,7, Tobias M. Boeckers1 & Andreas M. Grabrucker1,2
Phelan McDermid Syndrome (PMDS) is a genetic disorder characterized by features of Autism spectrum 
disorders. Similar to reports of Zn deficiency in autistic children, we have previously reported high 
incidence of Zn deficiency in PMDS. However, the underlying mechanisms are currently not well 
understood. Here, using inductively coupled plasma mass-spectrometry to measure the concentration 
of Zinc (Zn) and Copper (Cu) in hair samples from individuals with PMDS with 22q13.3 deletion including 
SHANK3 (SH3 and multiple ankyrin repeat domains 3), we report a high rate of abnormally low Zn/Cu 
ratios. To investigate possible underlying mechanisms, we generated enterocytes from PMDS patient-
derived induced pluripotent stem cells and used Caco-2 cells with knockdown of SHANK3. We detected 
decreased expression of Zn uptake transporters ZIP2 and ZIP4 on mRNA and protein level correlating 
with SHANK3 expression levels, and found reduced levels of ZIP4 protein co-localizing with SHANK3 
at the plasma membrane. We demonstrated that especially ZIP4 exists in a complex with SHANK3. 
Furthermore, we performed immunohistochemistry on gut sections from Shank3αβ knockout mice and 
confirmed a link between enterocytic SHANK3, ZIP2 and ZIP4. We conclude that apart from its well-
known role in the CNS, SHANK3 might play a specific role in the GI tract.
The Phelan McDermid Syndrome (PMDS/22q13.3 deletion syndrome) is a rare genetic disorder characterized 
by symptoms of the autism spectrum that go along with mental retardation, muscular hypotonia, and severely 
delayed language development. Additionally, patients can show minor facial dysmorphisms, decreased per-
ception of pain, and might suffer from seizures, ADD/ADHD (Attention Deficit Hyperactivity Disorder) and 
gastrointestinal (GI) problems1–3. PMDS is caused by a heterozygous deletion of the 22q13.3 region including 
SHANK3 (SH3 and multiple ankyrin repeat domains 3, also known as proline-rich synapse-associated protein 2 
(ProSAP2)). SHANK3 is a scaffolding protein of the postsynaptic density (PSD) of excitatory synapses4–6 known 
to be closely associated with autism spectrum disorders (ASD)7–11. De novo and inherited mutations in SHANK3 
have been found in individuals with ASD, and are present in about 0.69% of patients with ASD11. The protein has 
important functions at the synapse tethering receptors to the PSD, recruiting signaling complexes, and modu-
lating actin polymerization, which underlines the focus on the synaptic site as central factor in the etiology or 
pathophysiology of ASD.
Heterozygous loss of SHANK3 is considered to be the main cause for the neurological phenotype in PMDS 
since patients with small deletions or point mutations in the SHANK3 gene often develop a phenotype close to 
that of PMDS including intellectual and speech impairment, hypotonia and ASD1,12–14. A clear association of dele-
tion size and phenotype, however, could only be demonstrated for some features like developmental and language 
1Institute for Anatomy and Cell Biology, Ulm University, 89081 Ulm, Germany. 2WG Molecular Analysis of 
Synaptopathies, Neurology Dept., Neurocenter of Ulm University, 89081 Ulm, Germany. 3Institute of Neuroanatomy, 
Eberhard Karls University Tübingen, 72074 Tübingen, Germany. 4Institut Pasteur, Human Genetics and Cognitive 
Functions Unit, 75015 Paris, France. 5CNRS UMR 3571: Genes, Synapses and Cognition, Institut Pasteur, 75015 
Paris, France. 6University Paris Diderot, Sorbonne Paris Cité, Human Genetics and Cognitive Functions, 75013 Paris, 
France. 7FondaMental Foundation, 94010 Créteil, France. Correspondence and requests for materials should be 
addressed to A.M.G. (email:andreas.grabrucker@uni-ulm.de)
received: 15 June 2016
accepted: 22 February 2017
Published: 27 March 2017
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7:45190 | DOI: 10.1038/srep45190
delay as well as hypotonia for larger deletions, and ASD for smaller deletions15,16. Thus, the genotype-phenotype 
correlation in PMDS and SHANK3 mutations is quite complicated. While it seems that many mutations in 
SHANK3 lead to the clinical picture of PMDS, not all of them do. On the other hand, deletion of SHANK3 seems 
to be critical for the development of PMDS, but features of PMDS might be modified by other deleted genes.
Similar to many reports of Zn deficiency or decreased Zn/Cu (increased Cu/Zn) ratio in autistic children17–24, 
we have previously reported a high incidence rate of Zn deficiency in blood samples of PMDS patients that 
was associated with the occurrence of seizures, ADHD or other attention and hyperactivity issues, and signs of 
immunodeficiency25.
Zn has a central role for GI development26, brain development and for a functional immune system. In 
humans, Zn deficiency has additionally been associated with several neuropsychiatric diseases such as depression 
and autism27–31. However, the pathophysiological correlations between Zn, Cu and ASD or PMDS are, especially 
on a molecular level, currently not well understood. Recent research indicates a link between the dysfunctions 
associated with ASD, Zn deficiency and GI problems26. Children with ASD frequently suffer from GI problems 
such as diarrhea, constipation, bloating, abdominal pain, and gastroesophageal reflux26.
In animal models, severe prenatal Zn deficiency is associated with teratogenic effects32, while mild or late 
prenatal and early postnatal Zn deficiency result in much less defined clinical pictures. Here, Zn-related dys-
functions lead to behavioral abnormalities, such as reduced memory and learning capacity, increased anxiety, 
and autism-like behavior33,34. It was also shown that a low Zn level may lead to Cu toxicity28, which can cause 
neurological deficits in children.
Zn homeostasis is regulated by many different proteins involved in absorption, intracellular buffering, traf-
ficking and excretion, such as transporters of the ZIP (Zrt- and Irt-like proteins (SLC39A)) and ZnT (Zinc 
Transporter (SLC30A)) families, and metallothioneins (MTs). The main site of absorption of Zn is the small 
intestine, where Zn is absorbed by enterocytes. Of at least 10 ZnT and 15 ZIP transporters in human cells, sev-
eral are expressed in enterocytes and mediate the cellular uptake (mostly ZIP) and removal (mostly ZnT) of 
Zn29. In particular, ZIP1 (SLC39A1), ZIP2 (SLC39A2), and ZIP4 (SLC39A4) localize to the apical membrane of 
enterocytes and are strongly involved in Zn absorption35. In times of decreased dietary Zn intake, in mice, ZIP4 
is up-regulated underlining its function in the homeostatic control of Zn levels. Additionally, mutations in ZIP4 
are known to cause Acrodermatitis enteropathica, a rare autosomal recessive disorder of impaired Zn uptake in 
humans36.
To elucidate mechanistic insights on the dysregulation of heavy metal ions in ASD, we concentrated on one of 
the most prominent forms of syndromic ASD – PMDS. To that end we investigated Zn levels in PMDS individ-
uals with a heterozygous 22q13.3 deletion including SHANK3. We found a high incidence rate of Zn deficiency 
also in this group of patients, with a syndromic form of ASD. Thus, we analyzed enterocytes differentiated from 
patient derived induced pluripotent stem cells (iPSC). Interestingly, we found that SHANK3 is expressed both 
in human enterocytes and in gut epithelium of mice. In a screening approach with 27 trace metal homeostasis 
genes, the Zn transporters ZIP2 and ZIP4 were identified reduced in enterocytes differentiated from PMDS iPSC. 
Reduced expression of ZIP2 and ZIP4, was confirmed on both mRNA and protein level. In addition, a decreased 
amount of ZIP4 protein was detected in SHANK3 protein complexes at the cell surface. Endogenous protein lev-
els of SHANK3 seem to regulate the Zn transporter levels, as overexpression and knockdown experiments in cell 
lines demonstrated. Accordingly, low enterocytic SHANK3 levels result in diminished Zn transporter levels that 
could eventually explain reduced Zn concentrations in tissues and organs.
Results
Increased incidence of Zn deficiency and abnormal Zn/Cu ratio in individuals with 
PMDS. Determination of Zn levels in blood revealed an increased incidence rate of Zn deficiency in PMDS25. 
To substantiate our findings, we assessed Zn levels in hair samples via inductively coupled plasma mass spec-
trometry (ICP-MS). Metal levels in hair samples represent a mean concentration of approx. 2 months37. Zn and 
Cu concentrations of 31 individuals (15 males and 16 females) between 1 and 49 years of age diagnosed with 
PMDS were measured (Fig. 1a). Only participants with a genetically confirmed diagnosis of PMDS and deletions 
in 22q13 affecting the SHANK3 gene were included in the study. Minimum Zn concentrations were based on the 
levels necessary for individuals aged 1–12 that are less compared to those of adults. Eight participants (25.8%) 
were identified with Zn deficiency (Fig. 1a,b) and four showed abnormal high levels of Cu (Fig. 1a). Among a 
control group with age range and gender distribution similar to the group of participants with PMDS, an inci-
dence rate of only 8.7% was found (Supplementary Fig. 1a). This results in a 197% increased incidence rate of Zn 
deficiency in PMDS patients compared to healthy controls. Based on the values obtained, the Zn/Cu ratio was 
calculated, that is a recommended biomarker for ASD patients18,21,22. A Zn/Cu ratio below 6.5, the lower limit 
considered a normal range38, was found in ten participants (Fig. 1c,d). Among the participants with low Zn/Cu 
ratios, the majority were males (Fig. 1e). The occurrence of Zn deficiency alone (data not shown) or a low Zn/Cu 
ratio was not associated with acute gastro-intestinal problems (Fig. 1e) in PMDS patients. GI abnormalities were 
assessed categorized into “frequent GI infections”, “constipation”, “diarrhea”, “flatulence”, and “other GI problems 
(not specified)”. All sub-categories were represented to similar extent within the PMDS group. No GI problems 
were reported in the control group.
The fraction of individuals with low Zn/Cu ratio seems to slightly decrease with age (Supplementary Fig. 1b). 
Participants with low Zn/Cu ratio were frequently found to show symptoms of ADD/ADHD 
(Supplementary Fig. 1c,d) which is in line with recent findings of an abnormal Zn/Cu ratio in ADHD28,39.
We were able to document the trace metal profile of one PMDS patient who displayed low Zn levels and that 
was reported to have undergone Zn supplementation with 10 mg Zn per day for 3 weeks (Supplementary Fig. 1e,f) 
(Zn supplementation was performed independently of this study by the patient’s legal guardians). The results 
show a strong increase in Zn content after a period of Zn supplementation with only small effect on other trace 
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elements such as Cu, Pb, Hg, Fe, Ca, and Mg (Supplementary Fig. 1e). Accordingly, the Zn/Cu ratio showed a 
strong increase after Zn supplementation (Supplementary Fig. 1f) that went back to pretreatment values (Zn 
deficiency) after the discontinuation of the supplementation (Supplementary Fig. 1e,f).
Abnormal enterocyte Zn transporter expression in hiPSCs from PMDS patients. To investigate 
whether abnormal Zn/Cu levels result from impaired absorption in the GI tract, we generated enterocytes derived 
from iPS cells40 from two healthy and two PMDS individuals (Fig. 2a,b; Supplementary Fig. 2) including one 
patient with measured Zn deficiency, while Zn status of the other patient was unknown.
Differentiated cells from controls and patients were identified as enterocytes by the expression of the marker 
proteins Sucrase-Isomaltase (SI) and Peptidase 1 (SLC15A1) (Fig. 2c). A detailed analysis of mRNA expression 
profiles of trace metal homeostasis genes revealed no significant alterations in selected genes of Cu homeostasis 
(Fig. 2d). The level of ATP7A (ATPase Copper Transporting Alpha), a gene regulating Cu transport from the 
Figure 1. Zinc (Zn) and Copper (Cu) concentrations in the hair of individuals diagnosed with PMDS. (a–
d) Hair samples were collected from 31 participants diagnosed with PMDS (15 males and 16 females) between 
1 and 49 years of age (mean 8.3 years). (a) Concentrations of Zn and Cu were determined using ICP-MS and 
are shown in ppm. The patient marked with * was used for the generation of iPSC. (b) Eight participants were 
identified with Zn levels below the normal range (< 95 ppm) and four showed abnormal high levels of Cu  
(> 30 ppm). (c) The Zn/Cu ratio was calculated. A Zn/Cu ratio below 6.5 is considered below the normal range 
and was found in ten participants (32.3%). The grey zone in panel (d) marks the 6.5 cut-off limit. The dotted 
line corresponds to the average Zn/Cu ratio of patients without altered Zn/Cu ratio. (e) Of the participants with 
low Zn/Cu ratio, 60% were males. The occurrence of a low Zn/Cu ratio was not associated with gastro-intestinal 
(GI) problems given that 75% of participants with low Zn/Cu value did not report GI problems, similar to 86% 
of participants with normal Zn/Cu ratio.
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Figure 2. Expression-analysis of trace metal homeostasis genes in enterocytes derived from iPS cells from 
healthy and PMDS individuals. (a) Enterocytes were generated from 2 healthy controls and 2 PMDS patients. To that 
end, iPS cells were established from keratinocytes and differentiated into enterocytes (b). (c) Successful differentiation 
was controlled by expression analysis of the enterocyte marker proteins Sucrase-Isomaltase (SI) and Peptidase 1 
(SLC15A1). (d–f) Quantification of mRNA expression in lysate obtained from enterocytes. Results show data pooled 
from 2 controls and 2 PMDS patients. Experiments were performed in triplicates to analyze genes involved in (d) 
copper homeostasis, (e) homeostasis of iron and other divalent metal ions, and (f) zinc homeostasis. (d) No significant 
alterations were seen in ATPase Cu2+-transporting beta polypeptide (ATP7B), ATPase Cu2+-transporting alpha 
polypeptide (ATP7A), and copper metabolism (MURR1) domain containing 1 (COMMD1). (e) Zn binding proteins 
such as Matrix metalloproteinases (MMPs), Amyloid precursor protein (APP), chromatin modifying protein 2B 
(CHMP2B), divalent metal ion transporters (DMT1/SLC11A1, DMT2/SLC11A2, and SLC25A3) and genes involved 
in iron homeostasis such as Ferritin heavy chain (FTH1) and transferrin receptor 2 (TRF2) showed no significant 
changes. (f) Analyzing important Zn homeostasis genes of the metallothionein family (MT1A, MT2A, MT3), metal-
responsive transcription factor family (MTF1, MTF2), zinc transporter family (ZnT/SLC30A) and Zrt- and Irt-like 
proteins (ZIP/SLC39A), a trend towards increased levels of MT2A and a significant reduction in SLC39A2 (ZIP2) and 
SLC39A4 (ZIP4) (enlarged panel) was observed. (d-f) (t-test, n = 3 technical replicates from 2 cell lines per group; 
ZIP2 (CTRL vs. PMDS) p = 0.0033; ZIP4 (CTRL vs. PMDS) p = 0.0293).
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small intestine into the blood and leading to Cu deficiency if mutated, ATP7B (ATPase Copper Transporting 
Beta), a gene associated with copper excretion leading to increased copper levels if mutated, and COMMD1 
(Copper Metabolism Domain Containing 1), a regulator of copper homeostasis, were not different between 
Control and PMDS patient cells. Further, no significant alterations in selected genes involved in Fe homeostasis or 
general divalent metal transporters were seen (Fig. 2e). As expected for PMDS, a significant lower expression level 
of SHANK3 was detected in enterocytes (Supplementary Fig. 3). Interestingly, analyzing important Zn homeosta-
sis genes of the metallothionein family, metal-responsive transcription factor (MTF) family, zinc transporter fam-
ily (SLC30A), and Zrt- and Irt-like proteins (SLC39A) by a broad screening approach, revealed a trend towards 
increased levels of MT2A and a significant reduction in SLC39A2 (ZIP2) and SLC39A4 (ZIP4) was observed 
(Fig. 2f). Next we repeated the quantification of mRNA expression in lysate obtained from enterocytes for ZIP2 
and ZIP4 using a single-tube format instead of a 96 well approach, confirming equally successful differentiation 
of the patient iPS cells using Villin41 and CDX2 (caudal type homeobox 2)42 as markers (Fig. 3a). We could ver-
ify the significant decrease in ZIP2 and ZIP4 mRNA expression levels in PMDS patient samples compared to 
healthy controls (Fig. 3b). The alterations in ZIP2 and ZIP4 could also be confirmed on protein level (Fig. 3c). 
Quantification of protein expression in lysate obtained from enterocytes shows a significant reduction of ZIP2 in 
PMDS. In addition, a reduction of ZIP4 protein in samples from PMDS patients was observed as a clear trend.
Expression levels of ZIPs have been reported to respond to local Zn concentrations as part of a regulatory 
mechanism of Zn homeostasis and uptake. In mice, for example, ZIP4 expression increases under dietary Zn 
restriction43,44. We could observe similar regulatory processes in enterocytes derived from healthy individuals 
(Fig. 4a–d). After exposure to Zn depleted medium, the expression levels of ZIP2 and ZIP4 increase significantly 
in cells from unaffected individuals. Again, we could confirm a significant reduction of ZIP2 and ZIP4 expression 
levels in PMDS patient derived cells under these culture conditions (Fig. 4a,c). In addition, compared to controls, 
enterocytes from PMDS patients show significantly altered responses to changing Zn concentrations regarding 
the expression levels of ZIP2 and ZIP4. A significantly reduced up-regulation of ZIP2 can be seen in PMDS cells 
and an increased down-regulation after Zn supplementation (Fig. 4b).
Interaction of SHANK3 and enterocyte Zn transporters in hiPSCs. Using the above mentioned 
protocol, we found that the expression levels of SHANK3 that are significantly reduced in PMDS patient derived 
cells follow a similar expression pattern as seen for ZIP2 and ZIP4 (Fig. 5a). However, again, the up-regulation of 
SHANK3 mRNA in Zn depleted medium is less prominent in cells derived from PMDS patients (Fig. 5b).
SHANK3, which is localized within the cytoplasm and nucleus, but also at the membranes of enterocytes 
(Fig. 5c) shows overlapping localization with ZIP2 and ZIP4 (Fig. 5d). Moreover, using immunocytochemistry 
to quantify signal intensities of cell membrane associated ZIP2 and ZIP4, a significant reduction in ZIP4 was 
found in cells derived from PMDS patients (Fig. 5e,f). No significant reduction of membrane-associated ZIP2 was 
measured, pointing towards a reduction of the cytoplasmic rather than the membrane associated pool of the Zn 
transporter contributing to the observed reduction in overall protein levels (Fig. 5e).
As not only SHANK3 can be affected in PMDS, next, to investigate whether alterations in ZIP2 and ZIP4 are 
specifically dependent on SHANK3 protein levels, we performed overexpression or knockdown experiments of 
SHANK3 in Caco-2 cells (Fig. 6a,b; Supplementary Fig 4c–e). Caco-2 cells have been used to study the bioavail-
ability of micronutrients in the past45–47 and are a suitable model to study the mechanistic aspects of zinc uptake. 
Further, Caco-2 cells express SHANK3, ZIP2 and ZIP4. Knockdown of SHANK3, which results in approx. 50% 
reduction of SHANK3 (Supplementary Fig. 4a), leads to a significant reduction of ZIP4 signal intensity (Fig. 6a). 
For the analysis, the average ratio between signal intensities of transfected and neighboring untransfected cells 
was used and compared to the corresponding control. In addition, using Western Blot analysis, a reduction of 
both ZIP2 and ZIP4 was observed (Fig. 6b) under knockdown conditions, while only mRNA levels for ZIP4 are 
significantly decreased (Supplementary Fig. 4b). We did not observe increased expression of ZIP2 and ZIP4 after 
overexpression of SHANK3 on protein (Supplementary Fig. 4d) or mRNA level (Supplementary Fig. 4e), which 
could hint towards an upper limit of ZIP expression regulated by other factors.
After treatment of Caco-2 cells with exogenous Zn, cells overexpressing SHANK3 displayed more nuclear 
SHANK3 signals and Zn-loaded vesicles with membranes showing SHANK3 signals (Supplementary Fig. 4c). 
Overexpression of a mutated SHANK3 protein (GFP-SHANK3 R1119X) that has been associated with schizo-
phrenia and that is permanently localized in the nucleus48 does not result in a significant increase in ZIP2 and 
ZIP4 mRNA and protein levels. However, a clear trend towards an increase is visible (Supplementary Fig. 4f,g).
Incubation of Caco-2 cells with ZnCl2 solution for 30 min results in a significantly lower fluorescent signal 
intensity of Zinquin ethyl ester, a membrane permeable Zn fluorophore in SHANK3 knockdown cells compared 
to cells expressing scrambled RNAi (Fig. 6c), hinting at a reduced uptake of Zn in SHANK3 knockdown cells. In 
Caco-2 cells, across a broad spectrum of Zn levels induced by Zn depletion and supplementation, levels of ZIP2 
and ZIP4 assessed by immunocytochemistry are reduced in SHANK3 knockdown cells compared to cells express-
ing scrambled RNAi (Supplementary Fig. 5).
Intriguingly, in line with the decrease observed in ZIP4 but not ZIP2 cell surface signal intensity (Fig 5e), 
using anti-SHANK3 coupled beads to precipitate SHANK3 in lysate from human iPSC derived enterocytes, we 
primarily found ZIP4 in a complex co-immunoprecipitated with SHANK3 (Fig. 6d). While there was also a some-
what weaker signal for ZIP2, ZIP2 showed some amount of unspecific binding to the beads (CoIP Ctrl).
Interaction of SHANK3 and enterocyte Zn transporters in mice. Similarly to enterocytes dif-
ferentiated from hiPSCs, SHANK3 was found expressed in the GI epithelium of mice (Fig. 7a). Using 
co-immunoprecipitation experiments, we found primarily ZIP4 and to a much lesser extend ZIP2 in a complex 
with SHANK3 in lysate from mouse GI epithelium (Fig. 7b). Moreover, similar to hiPSC, using measurements 
of ZIP2 and ZIP4 GI sections from WT and Shank3αβ KO mice, a significant reduction in ZIP2 fluorescence 
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intensity of the tissue sections and a trend towards a reduction of ZIP4 fluorescence intensity of the tissue sec-
tions in Shank3αβ KO mice was detected (Fig. 7c,d). These results argue for functional changes in vivo such as 
impaired Zn absorption.
Discussion
A growing amount of research indicates that abnormalities in the GI system during development might be a fac-
tor in ASD. Many patients with ASD have symptoms associated with GI disorders and, especially in young age, 
show a high prevalence for Zn deficiency. In previous studies, we could show that animals with prenatal zinc defi-
ciency display autism like features25,34. Further, male mice lacking vesicular zinc in the brain were reported to dis-
play ASD like behavior49. Therefore, it is possible that the development of ASD is facilitated by Zn deficiency. Of 
the few studies performed with autistic patients using Zn supplementation, the results show that autistic children 
Figure 3. Analysis of ZIP2, ZIP4 and Zn biology in enterocytes from healthy and PMDS individuals. 
(a,b) Quantification of mRNA expression in lysate obtained from enterocytes. Results show data pooled 
from 2 controls and 2 PMDS patients. Smaller inserts (top right of graphs) show individual data points for 
each measurement and cell line per group. (a) Villin and CDX2, markers for enterocyte differentiation verify 
that no differences in differentiation - efficiency between Controls and the two PMDS patients were present 
(t-test, n = 3 technical replicates from 2 cell lines per group; Villin (CTRL1 vs. CTRL2) p = 0.161; (PMDS1 
vs. PMDS2) p = 0.331; (pooled CTRL vs. PMDS) p = 0.8547 (n = 6); Cdx2 (CTRL1 vs. CTRL2) p = 0.4043; 
(PMDS1 vs. PMDS2) p = 0.3244; (pooled CTRL vs. PMDS) p = 0.5894 (n = 6)). (b) Using a single-tube format, 
the significant decrease in ZIP2 and ZIP4 mRNA expression levels in PMDS patient samples compared to 
healthy controls was confirmed (t-test, n = 3 technical replicates from 2 cell lines per group; ZIP2 (CTRL1 
vs. CTRL2) p = 0.5352; (PMDS1 vs. PMDS2) p = 0.0237; (pooled CTRL vs. PMDS) p = 0.0033 (n = 6); ZIP4 
(CTRL1 vs. CTRL2) p = 0.1249; (PMDS1 vs. PMDS2) p = 0.5254; (pooled CTRL vs. PMDS) p = 0.043 (n = 6)). 
(c) Quantification of protein expression in lysate obtained from enterocytes. Results show data pooled from 2 
controls and 2 PMDS patients. The right panels show individual data points for each measurement and cell line 
per group. Three technical replicates were performed per patient/control and the expression levels normalized 
to Actin. A significant reduction of ZIP2 protein levels can be seen in PMDS patient samples and a clear trend 
for a reduction in ZIP4 (t-test, ZIP2 (CTRL1 vs. CTRL2) p = 0.119; (PMDS1 vs. PMDS2) p = 0.1773; (pooled 
CTRL vs. PMDS) p = 0.0478 (n = 6); ZIP4 (CTRL1 vs. CTRL2) p = 0.9232; (PMDS1 vs. PMDS2) p = 0.0817; 
(pooled CTRL vs. PMDS) p = 0.063 (n = 6)).
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with gastro-intestinal co-morbidities significantly improved with respect to hyperactivity and self-stimulatory 
behavior after Zn therapy50. However, detailed studies in human PMDS patients are missing so far.
Here, we investigated whether the observed increased incidence rate of Zn deficiency in ASD also occurs 
in one of the most prominent syndromic forms of ASD, PMDS, as here, a clear genetic cause is underlying the 
disorder. Surprisingly, we also found a high incidence rate of Zn deficiency in PMDS patients by analyzing hair 
samples. At present, about 1000 cases of PMDS are diagnosed worldwide. The prevalence is given as 2.5 to 10 
cases per million births51. However, it is known from recent studies on large cohorts of autistic patients that the 
proportion of patients with PMDS lies at about 0.5% within ASD. Thus, the syndrome could be significantly 
under-diagnosed. Here, we measured hair samples of 31 patients that have clear diagnosis of PMDS and that have 
not been sampled in our previous study, where Zn levels of 37 participants were determined in blood25. Hair and 
blood Zn values correlate with the advantage of the measurement of hair being more reproducible and sensi-
tive37,52. Systemic Zn deficiency as assessed in hair or blood samples was published to affect also brain tissue, with 
up to 30% decreased Zn concentrations in hippocampus and cerebral cortex accompanied by reduced learning 
behavior in a rat model of diet-induced Zn deficiency53,54.
Figure 4. Enterocytes from Controls and PMDS patients were analyzed after exposure to Zn depleted 
medium and medium supplemented with 10 μM Zn2+ for 20 h. mRNA expression is shown as mean Δ ct 
values from 3 technical replicates from two controls and two patient cell lines each. (a, c) Smaller inserts (top 
right of graphs) show individual data points for each measurement and cell line per group. (a) Compared 
to Controls, a significant reduction of ZIP2 expression levels can be found in PMDS patient derived cells 
under all conditions (2-way ANOVA, main effect of group: F(1,29) = 99.320 p < 0.001; Post hoc analysis Ctrl 
vs. PMDS: Zn depleted p < 0.0001, Control p = 0.0478, Zn suppl. p = 0.7079. Main effect of treatment: 
F(1,29) = 47.531 p < 0.001; Post hoc analysis Ctrl vs. PMDS: Zn depleted p < 0.0001. Main effect treatment x 
group: F(1,29) = 46.340 p < 0.001). (b) The increase of ZIP2 expression after exposure to Zn depleted medium, 
and decrease after exposure to Zn supplemented medium, is significantly altered in PMDS patient enterocytes 
(two tailed t-test, Ctrl vs. PMDS: Zn depleted p = 0.0787 (indicated as trend “#”), Zn suppl. p = 0.0435). (c) 
Compared to Controls, a significant reduction of ZIP4 expression levels can be found in PMDS patient derived 
cells under all conditions (2-way ANOVA, main effect of group: F(1,29) = 20.044 p < 0.001; Post hoc analysis 
Ctrl vs. PMDS: Zn depleted p = 0.0217, Control p = 0.043, Zn suppl. p = 0.0007. Main effect of treatment: 
F(1,29) = 12.362 p < 0.001; Post hoc analysis Ctrl vs. PMDS: Zn depleted p = 0.042. Main effect treatment x group: 
F(1,29) = 1.132 p = 0.336). (d) The expected response of ZIP4 expression to Zn depleted and Zn supplemented 
medium is similar in enterocytes from Control and PMDS individuals (two tailed t-test, Ctrl vs. PMDS: Zn 
depleted p = 0.8468, Zn suppl. p = 0.4489). (a–d) Asterisks above bars show significance compared to the 
control condition, asterisks in between bars compare the two groups (CTRL and PMDS) within a condition.
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Compared to large-scale studies involving hundreds of patients with autism23, the sample size of our study is 
rather small. However, compared to the overall number of diagnosed cases, our two studies cover a wide spec-
trum of patients located on different continents (North America, Europe, South America). From 68 patients over-
all combined from both studies, 15 (22.1%) were found to have mild to severe Zn deficiency and the high number 
of 27 (42.2% based on 64 samples with determination of both Zn and Cu) display low Zn/Cu ratios.
As with Zn deficiency in autism, a major and unresolved question concerns the cause for Zn deficiency. While 
maternal Zn deficiency during pregnancy might be a major risk factor for autism26,55, in PMDS and probably 
also some cases of autism, other factors may be involved. Interestingly, in this study, one Zn deficient patient was 
treated for his Zn deficiency after the initial hair measurements by the family physician. The patient was supple-
mented with 10 mg Zn per day for 3 weeks (20 days). After the supplementation, we were able to obtain fresh hair 
Figure 5. Interaction of SHANK3 and Zn transporters. (a) Differentiated enterocytes were analyzed after 
exposure to Zn depleted and supplemented (with 10 μ M Zn2+) medium for 20 h. mRNA expression levels 
are shown as mean Δ ct values from 3 technical replicates from two controls and two patient cell lines each. 
Smaller insert (top right of graphs) shows individual data points for each measurement and cell line per group. 
Compared to Controls, a significant reduction of SHANK3 expression levels can be found in PMDS patient 
derived cells under most conditions (2-way ANOVA, main effect of group: F(1,30) = 9.716 p < 0.004; Post hoc 
analysis Ctrl vs. PMDS: Zn depleted p = 0.051 (indicated as trend #), Control p = 0.0461, Zn suppl. p = 0.0096. 
Main effect of treatment: F(1,30) = 8.056 p < 0.002; Main effect treatment x group: F(1,30) = 2.589 p = 0.092). (b) 
The SHANK3 mRNA expression level shows a similar reaction to media with specific Zn concentration as seen 
for ZIP2 and ZIP4. The up-regulation of SHANK3 mRNA in Zn depleted medium is significantly less in cells 
derived from PMDS patients (two tailed t-test, Ctrl vs. PMDS: Zn depleted p = 0.055 (indicated as trend #), Zn 
suppl. p = 0.9024). (c) Immunocytochemistry labeling of SHANK3 reveals cytoplasmic but also nuclear (full 
arrow) and membrane associated (open arrow) signals of SHANK3. (d) Membrane associated SHANK3 co-
localizes with ZIP2 (upper panel) and ZIP4 (lower panel) fluorescent signals. (e) A significant reduction of ZIP4 
signal intensities is seen in PMDS patients compared to controls (t-test, ZIP2 (CTRL1 vs. CTRL2) p = 0.0808; 
(PMDS1 vs. PMDS2) p = 0.1431; (pooled CTRL vs. PMDS) p = 0.7138 (n = 20); ZIP4 (CTRL1 vs. CTRL2) 
p = 0.7176; (PMDS1 vs. PMDS2) p = 0.3428; (pooled CTRL vs. PMDS) p = 0.0006 (n = 20)). Smaller insert (top 
right of graphs) shows individual data points for each measurement and cell line per group. (f) For the analysis 
of signal intensities, cell surface signals were selected and quantified from at least 20 optic fields of view from 
two patients and two controls.
www.nature.com/scientificreports/
9Scientific RepoRts | 7:45190 | DOI: 10.1038/srep45190
samples and analyzed only few millimeters grown in the period of Zn supplementation. The results imply that Zn 
absorption is not completely blocked in PMDS and the Zn status can reach normal levels after increased daily Zn 
uptake. After discontinuation of the supplementation, the patient again developed a Zn deficiency. The potential 
to compensate a dysregulation of Zn transporters by external factors such as high Zn intake may be a reason why 
not every patient, but all patient iPSC lines studied show similar molecular alterations. Contrary to defined cell 
culture media, PMDS patients are exposed to a variety of factors influencing Zn status including food habits and 
preferences, as well as physical activity.
Several possible reasons for inefficient Zn absorption might be discussed. One of them could be altered 
expression of Zn transporters and homeostasis genes due to abnormalities in the GI system. In search for such 
Figure 6. Knockdown of endogenous SHANK3 in Caco-2 cells. Caco-2 cells were transfected with SHANK3 
shRNA co-expressing GFP and the corresponding control, a scrambled shRNA. (a) The average cytoplasmic 
ZIP2 or ZIP4 signal intensity was measured in transfected (full arrow) cells and neighboring untransfected 
cells (open arrow) and the mean ratio of n = 10 cells is shown. Knockdown of SHANK3 leads to a significant 
reduction in ZIP4 signal (t-test, p = 0.0015). (b) Western blot analysis of protein lysate from Caco-2 cells reveals 
a significant decrease of ZIP2 and ZIP4 levels normalized to the corresponding control. (n = 3, for statistical 
analysis, all values were normalized to untransfected controls (Control) and the ratio of scrambled RNAi/
Control and SHANK3 RNAi/Control compared) (t-test, ZIP2: p = 0.001; ZIP4: p = 0.0052). (c) Caco-2 cells 
were transfected with scrambled RNAi (scrRNAi) or SHANK3 specific RNAi for 3 d. 50 μ M ZnCl2 were added 
for 30 min and intracellular Zn2+ visualized by Zinquin ethyl ester labeling. The Zinquin fluorescence intensity 
was measured and the ratio between a transfected (full arrow) and untransfected (open arrow) cell calculated. 
Images for Zinquin show signal intensity color-coded. A significantly (p = 0.0254, t-test, n = 10) lower Zinquin 
signals can be seen in cells expressing the SHANK3 targeting RNAi compared to cells expressing scrRNAi. (d) 
CoIP experiments using lysate from hiPSC derived enterocytes. All analyzed proteins (SHANK3, ZIP2, ZIP4) 
were found expressed in enterocytes (Input). Rat brain lysate was used to compare SHANK3 antibody signals in 
human samples. Anti-SHANK3 antibody was bound to magnetic beads and precipitated. Anti-ZIP4 and anti-
ZIP2 were used for detection of possibly co-immunoprecipitated proteins. ZIP4 and to a lesser amount ZIP2 
were found co-immunoprecipitated in the analyzed eluate (CoIP Eluate), while no clear band or enrichment 
was visible in the eluate from a reaction without SHANK3 antibodies coupled to beads (CoIP Ctrl). ZIP2 signals 
are generally low in lysate from Caco-2 and enterocytes due to low protein expression levels.
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molecular mechanisms that might be responsible for the Zn malabsorption we made use of a cellular in vitro sys-
tem and employed enterocytes generated from iPSC from PMDS patients in comparison to healthy controls. In 
a comprehensive screen for proteins regulating heavy metal ions in the body we investigated the expression of 27 
Zn homeostasis genes. These included the two families of Zn transporters with ZnT1–8 (SLC30A1-8) and ZIP1-
14 (SLC39A1-14). A significant decrease of ZIP2 and ZIP4 mRNA levels was found and confirmed in single-tube 
qRT-PCR. On protein level, for ZIP4, a significant loss of transporters at the membrane occurs and the analysis of 
cell protein homogenate reveals a strong trend towards a decrease in total ZIP4 and a significant decrease in ZIP2.
Both, ZIP2 and ZIP4 have been shown to regulate Zn uptake into enterocytes. In particular, mamma-
lian ZIP4 is involved in Zn uptake in enterocytes and embryonic visceral endoderm cells. Both, the level of 
mRNA abundance and subcellular localization of ZIP4 change in response to Zn levels56. Mutations in ZIP4 
cause Acrodermatitis enteropathica (AE), a rare and untreated lethal genetic disorder of Zn uptake in humans. 
Intriguingly, mental problems have been described in AE patients such as irritability, a complete lack of smiling 
and laughing, and an avoidance of eye contact as seen in autistic children57. However, dietary Zn supplementation 
can suppress the symptoms of this disease58–60, probably due to the activation of other Zn uptake transporters 
such as ZIP1-361. The compensatory regulation of ZIP2 was affected in PMDS hiPSCs. Thus, on the level of the 
individual, one might speculate that in case of exposure to low zinc supply, the decreased expression of ZIP2 and 
ZIP4 and the altered ability to compensate via regulation of ZIP2 might lead to an increased risk to develop Zn 
deficiency in PMDS patients.
An interesting observation was the fact that the expression of ZIP genes was dependent upon SHANK3 expres-
sion levels. Even though no association has been made so far between control of Zn homeostasis and other 
deleted genes in the PMDS iPS cell lines used in the study (see Supplementary Table 1), it may have been possi-
ble that some have an effect on Zn transporters as well. Therefore, knockdown and overexpression experiments 
specific for SHANK3 were performed in Caco-2 cells. Caco-2 cells showed reduced levels of ZIP4 after SHANK3 
knockdown on mRNA level, and protein level assessed by protein biochemistry and immunocytochemistry. 
Interestingly, after incubation with ZnCl2, less uptake of Zn was detected in SHANK3 knockdown cells underlin-
ing the physiological relevance of the reduction of ZIP4 in these cells.
Figure 7. SHANK3 expression and association with ZIP2 and ZIP4 in mice. (a) Expression-analysis of 
SHANK2 and SHANK3 in wildtype mice (n = 3). Both SHANK2 and SHANK3 are expressed in GI epithelium. 
(b) CoIP experiments using lysate from GI epithelium. All analyzed proteins (SHANK3, ZIP2, ZIP4) were 
found expressed in GI epithelium (Input). SHANK3 was bound to magnetic beads and ZIP4 and ZIP2 were 
found co-immunoprecipitated in the analyzed eluate (CoIP Eluate), while no clear band or enrichment 
was visible in the eluate from a reaction without SHANK3 antibodies coupled to beads (CoIP Ctrl). (c,d) 
Immunohistochemistry performed on WT and Shank3αβ KO mice (n = 3, 10 weeks of age) reveals a significant 
reduction in ZIP2 fluorescence intensity and a trend towards a reduction of ZIP4 fluorescence intensity in 
Shank3αβ KO mice compared to WT (t-test, ZIP2: p = 0.01; ZIP4: p = 0.08). For the analysis, fluorescence 
signal intensity of ZIP2 and ZIP4 positive signals of at least 10 different regions from multiple sections were 
analyzed.
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While overexpression does not lead to increased ZIP2 or ZIP4 concentrations, overexpression of a SHANK3 
protein with mostly nuclear localization slightly increased both mRNA and protein levels of ZIP2 and ZIP4. 
Moreover, in PMDS cells, these transporters lost their sensitivity to surrounding Zn concentrations. Further 
investigations revealed that ZIP4 physically interacts with SHANK3 in enterocytes differentiated from hiPSCs 
and mouse epithelium, and that primarily ZIP4 can be found in a protein complex with SHANK3.
The data indicate that SHANK3 might be involved in a regulatory pathway for Zn concentrations by direct 
interaction with Zn transporters at the enterocyte membrane as well as a transcriptional regulator for essential 
Zn transporters. At the moment it still needs to be elucidated how SHANK3 can mediate a regulatory role on 
transcriptional events, however, the ability of the protein to localize to the nucleus48,62 and data presented here 
might indicate that SHANK3 can not only function as a scaffolding molecule but also as a component of tran-
scriptional complexes. In turn, this would imply that mutations of the SHANK3 gene can directly cause alterations 
of transcriptional activity in defined tissues and cell types. A more detailed analysis of surface localization and 
expression of ZIP2 and ZIP4 in SHANK3 knockdown and after nuclear localization of SHANK3 should be per-
formed in future studies.
The presence of other “synaptic” proteins in the GI epithelium makes the existence of a protein complex sim-
ilar to the one described at excitatory postsynapses in enterocytes more than likely. One feature of this complex 
seems to be the regulation of two Zn importers, ZIP2 and ZIP4 by interacting protein networks and possibly 
nuclear signaling of SHANK348,62. Future research will have to investigate whether the deregulation of Zn home-
ostasis is a common feature of mutations in “synaptic” proteins that are also found in the GI system. The high 
incidence of trace metal imbalances in patients with autism but also other synaptopathies might hint towards 
such a common mechanism.
Whenever detected, the treatment of Zn deficiency by oral Zn supplementation is in general advised since 
persistent Zn deficiency can cause serious health problems including growth impairment, immunological and 
gastrointestinal problems and neurological symptoms21,63. Together with the fact that Zn deficiency can contrib-
ute to and modify disease symptoms in ASD26,55, our data implies that Zn therapy should be considered in PMDS 
and Autism patients as the risk to develop Zn deficiency might be high. Especially, as marginal Zn deficiency in 
humans often is undetected. Whether Zn therapy also is helpful in absence of Zn deficiency for PMDS or Autism 
patients with mutation in SHANK3 needs further investigation and new strategies for Zn delivery bypassing clas-
sical Zn uptake pathways may be required.
Materials and Methods
Materials. mTeSR1 was purchased from Stem Cell Technologies. RPMI advanced, RPMI 1640, DMEM, 
DMEM/F12, GlutaMAX, DPBS without Ca2+/Mg2+, FBS (#10500), Mem Non Essential Amino Acids, Antibiotic-
Antimycotic, and TrypsinLE Express were obtained from Gibco. Activin A and FGF-2 were purchased from Cell 
Guidance Systems and EGF from Invitrogen. Matrigel (hESC qualified) was obtained from BD Biosciences. PBS 
with Ca2+/Mg2+ was purchased from PAA. Zinc chloride was obtained from Sigma. Paraformaldehyde was pur-
chased from Merck and D-Saccharose was from Roth. Primary antibodies anti-SI (Sucrase-Isomaltase) (dilution 
1:300) and anti-SLC15A1 (Peptidase 1) (dilution 1:300) were purchased from Sigma, anti-SLC39A2 (ZIP2) (dilu-
tion 1:10000 ICC; 1:1000 IHC, WB, IP) and anti-SLC39A4 (ZIP4) (dilution 1:200 ICC, IHC; 1:250 WB, IP) from 
Abcam and Alexa Fluor conjugated secondary antibodies and ProLong® Gold antifade reagent from Invitrogen. 
For SHANK3 immunoprecipitation and western blotting in-house polyclonal rabbit SHANK3 antibodies were 
used that have been described previously25,64 (dilution 1:400). iScriptTM cDNA Synthesis Kit, SSoAdvanced 
Universal SYBR® Green Supermix and customized PrimePCR plates were purchased from Bio-Rad. QuantiTect 
Primer Assays, RNeasy Mini Kit and QuantiFastTM SYBR_Green RT-PCR kit were purchased from Qiagen. 
Chelex-100 Resin was obtained from Bio-Rad. CuSO4*5H2O was obtained from Roth. MgSO4*7H2O was pur-
chased from Merck. μ MACSTM Protein G kit and μ MACSTM Separator were purchased from Miltenyi Biotec.
Analysis of hair zinc and copper in human participants. Patients were enrolled from the “Medical 
management for children with Phelan McDermid syndrome program” at the Department of Child and Adolescent 
Psychiatry, Ulm University and the Phelan McDermid syndrome family conference at Wartaweil, Germany. After 
informed consent of the participants or their legal guardians, a strand of hair was cut close to the scalp at the back 
of the heads. The hair sample was weighted and after anonymization sent to Torre GmbH (Brandstätterstraße 1, 
90513 Zirndorf, Germany) for ICP-MS analysis of zinc and copper. Samples were matched for hair color between 
both groups. 31 PMDS patients between 1 and 49 years were analyzed (40% female, 60% male). 84% of the 
patients suffered from infantile hypotonia and 100% of the patients presented speech delay. None of the par-
ticipants took zinc or mineral supplements. Reference range was 94–306 ppm for zinc and 10–30 ppm for cop-
per. Reference values were calculated as described by Yasuda et al.23 and compared to reference values initially 
obtained from healthy normal children and adults65 and a study on Vancouver preschoolers aged 2–5 year-old37,66. 
The mean Zn level from all participants aged 1–12 was calculated and the obtained standard deviation (SD) mul-
tiplied by 2. Values outside 2SD were considered abnormal. The reference range obtained by this method in our 
study was similar to the range published before23.
The patient study was approved by the ethics committee of Ulm University (proposal no. 213/13) and carried 
out in accordance with the approved guidelines. Hair samples were cut after written informed consent of the study 
participants or their legal guardians.
Animals. Shank3αβ mutants were generated by Genoway (Lyon, France) and raised on a C57BL/6 back-
ground and have been characterized before64. All animal experiments were performed in accordance with the 
guidelines and regulations for the welfare of experimental animals issued by the Federal Government of Germany 
and by the local ethics committee (Ulm University) ID Number: O.103. The protocol used was approved by the 
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Regierungspräsidium Tübingen, state of Baden-Württemberg, and the ethics committee of Ulm University (ID 
Number: O.103). Both male wild type and Shank3αβ KO mice received the same standard laboratory diet (ssniff 
GmbH, Germany) with adequate Zn supply and consumed similar amounts of food and water that was accessed 
ad libitum. The housing room was maintained at 22◦C, with lights automatically turned on/off in a 12 h rhythm 
(lights on at 7 am).
Stem cell-differentiation into enterocyte-like cells. The differentiation was performed using a pro-
tocol by Iwao et al.40. Human induced pluripotent stem cell lines between passages 15 and 2067 were grown to 
70% confluence in mTeSR1 stem cell medium. Differentiation to definite endoderm was initiated by changing 
the medium to RPMI advanced supplemented with 2 mM GlutaMAX, 0.5% FBS, 100 ng/ml Activin A and 1% 
Antibiotic-Antimycotic. After 48 h, cells were grown in RPMI advanced supplemented with 2 mM GlutaMAX, 
2% FBS, 100 ng/ml Activin A and 1% Antibiotic-Antimycotic for 24 h. The medium was changed to DMEM/F12 
GlutaMAX containing 2% FBS, 250 ng/ml FGF-2 and 1% Antibiotic-Antimycotic for 96 h. FGF-2 is known to 
drive differentiation from definite endoderm to intestinal stem cells. Subsequently cells were treated with 10 μ M 
ROCK Inhibitor (Ascent Scientific) for 1 h, detached with TrypLE and plated on Matrigel coated 12-well plates. 
The cells were cultured in DMEM/F12 + GlutaMAX, 2% FBS, 1% NEAA, 2% B27, 1% N2, 20 ng/ml EGF, and 1% 
Antibiotic-Antimycotic. B27 and N2 were purchased from GIBCO. Medium was changed every 3 days. The cells 
were harvested after 3 weeks.
Zn depletion in enterocyte-like cells. For the production of Zn deficient medium, DMEM/
F12 + GlutaMAX, 2% FBS, 1% NEAA was depleted of all divalent cations by Chelex-100 (Bio-Rad) purifica-
tion according to the manufacturer’s protocol as previously described68 and subsequently supplemented for all 
divalent cations present in DMEM/F12 + GlutaMAX except for ZnSO4*4H2O (1.0505 mM CaCl2, 5.2E-6 mM 
CuSO4*5H2O, 1.2376E-4 mM Fe(NO3)3*9H2O, 0.0015 mM FeSO4*7H2O, 0.3005 mM MgCl2*6H2O, 0.4065 mM 
MgSO4*7H2O). After reestablishment of original cation concentrations, the pH of the medium was readjusted 
with HCl. 2% B27, 1% N2 and 20 ng/ml EGF were added prior to use. Enterocytes were treated for 20 h with either 
Zn deficient medium, 10 μ M ZnCl2 supplemented medium or left untreated.
SHANK3 Overexpression and Knockdown in Caco-2 colorectal adenocarcinoma cell 
line. pCMV-MYC (Clontech), MYC tagged SHANK3 and SHANK3 RNAi constructs and the SHANK3-R119X 
mutant construct have been used and characterized previously48,69. For immunocytochemistry, cells were trans-
fected using the ScreenFect A-plus Transfection Kit (Genaxxon bioscience) according to the manufacturer’s pro-
tocol. Cells were imaged or harvested after 3 days. For mRNA analysis and protein biochemistry, Caco-2 cells 
were transfected with the Nucleofector 4D –X (Lonza, program DG-113) and the SE Cell Line 4D-Nucleofector® 
X Kit (Lonza) according to the manufacturer’s protocol. 2 × 106 cells and 8 μ g DNA were used per cuvette. Three 
days after transfection, Caco-2 cells were treated with 100 μ M TPEN, 50 μ M ZnCl2 for 30 minutes at 37 °C or left 
untreated. Transfection efficiency was estimated to 40%.
Immunocytochemistry. After fixation in 4% Paraformaldehyde/10% Sucrose, the cells were washed with 
PBS and permeabilized with 0.2% Triton X-100 in PBS for 5 min. Subsequently, blocking solution (5% FBS in 
PBS) was applied for 1 h. Cells were incubated with the primary antibodies at 4 °C over night. After washing 3x 
with PBS, the cells were incubated with Alexa Fluor conjugated secondary antibody at room temperature for 1 h. 
After washing 2x with PBS and 1x with sterile millipore water, cells were mounted with ProLong® Gold antifade 
reagent with DAPI.
For fluorescent staining of Zn, Zinquin ethyl ester was used. A 5 mM stock solution in DMSO was stored at 
− 20 °C and applied to Caco-2 cells in a concentration of 25 μ M for 1 h at RT along with the secondary antibody 
during immunofluorescence staining.
Immunohistochemistry. Paraffin embedded sections from intestine were obtained of small intestine from 
adult mice (10 weeks of age). From each intestine, 4 cm were fixed in 4% buffered formalin. Per sample, three 
small parts were embedded in paraffin wax longitudinally (for cross sections). After cutting of paraffin embedded 
sections, (4.5 to 5 μ m thick) sections were treated 2x with Xylene for 5 min and 100%, 90%, 70% Ethanol and H2O 
for 5 min each. Subsequently, sections were boiled in 10 mM Sodium Citrat buffer pH 6.0 (Microwave: 15 min 
600 W around boiling point). Afterwards the slides were cooled down to room temperature (RT) for approxi-
mately 30 min und washed two times in PBS for 2 min each. The tissue on each slide was surrounded with a fat 
tissue stick. To avoid unspecific antibody binding the tissue was blocked with blocking solution (BS) for 1 h at 
RT. Subsequently, the tissue was incubated with primary antibody diluted in BS for 2 h at RT in a humid cham-
ber. After washing 3x with PBS for 5 min, the tissue was incubated with secondary antibody, diluted in BS, for 
1 h in a humid chamber, followed by a wash step with PBS for 5 min. The tissue was counterstained with DAPI 
(4′ ,6-Diamidin-2-phenylindol). Fluorescence images were obtained using an upright Axioscope microscope 
equipped with a Zeiss CCD camera (16 bits; 1280 × 1024 ppi) using Axiovision software (Zeiss) and analyses of 
signal intensities of the tissue sections were performed with ImageJ 1.48r.
Cell lysis and RNA preparation. Cells were harvested and resuspended in 600 μ l RIPA buffer, and kept for 
30 min on ice. Lysate was cleared from debris by centrifugation (14000 rpm, 15 min) and stored at − 80 °C with 
Protease Inhibitor. Alternatively, lysate from gut epithelium of mice was used. Total RNA was isolated with the 
RNeasy Mini Kit according to the manufacturer’s protocol. All of the optional purification steps were performed 
and RNA eluted with sterile RNAse free water.
www.nature.com/scientificreports/
13Scientific RepoRts | 7:45190 | DOI: 10.1038/srep45190
qRT-PCR. cDNA synthesis of pooled RNAs was performed with the iScriptTM cDNA Synthesis Kit (Bio-Rad) 
according to the manufacturer’s protocol in a total reaction volume of 20 μ l and a maximum of 1 μ g RNA/reac-
tion. Quantitative real-time-PCR was performed using the SSoAdvanced Universal SYBR® Green Supermix 
(Bio-Rad) and customized PrimePCR plates in 96 well format with immobilized primers (Bio-Rad) according to 
the manufacturer’s protocol with a final reaction volume of 20 μ l and 2 ng cDNA/well. Resulting data was analyzed 
using the hydroxymethylbilane synthase (HMBS) or Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene 
as an internal standard to normalize transcript levels. Cycle threshold (ct) values were calculated by CFX Manager 
(version 3.1). All quantitative real-time PCR reactions were run in technical duplicates for each of the 2 patient 
and control cell lines and mean ct-values for each reaction were taken into account for calculations.
Alternatively, first strand synthesis and quantitative real-time-PCR amplification were performed in a 
one-step, single-tube format using the QuantiFastTM SYBR_Green RT-PCR kit from Qiagen according to the 
manufacturer’s protocol in a total volume of 20 μ l. Thermal cycling and fluorescent detection were performed 
using the Rotor-Gene Q real-time PCR machine (model 2-Plex HRM) (Qiagen). The SYBR Green I reporter dye 
signal was measured. Resulting data were analyzed using the HMBS gene as an internal standard to normalize 
transcript levels. Cycle threshold (ct) values were calculated by the Rotor-Gene Q Software (version 2.0.2). All 
quantitative real-time PCR reactions were run in technical triplicates for each of the 2 patient and control cell 
lines and mean ct-values for each reaction were taken into account for calculations.
Protein biochemistry. To obtain homogenate from GI tissue, small intestinal epithelium was isolated from 
mesenchyme following a protocol after Nik and Carlsson70. In brief, small intestine was cut into 4–5 cm long 
pieces. Gut mucus is removed by gently squeezing it out of the intestine with the blunt point of tweezers. Each 
piece was inverted by inserting a rod securing the intestine at one end with a suture and pulling the rod back. The 
rod with the inverted piece was inserted into a pipet tip (1000 μ l) and one end of the intestine pulled onto the tip. 
After careful removal of the rod, the second end of the intestinal piece is pinched off with a suture. The inverted 
intestine with the attached pipet tip is submerged in cell recovery solution and repeatedly in- and reflated with air 
over the course of at least 30 min per piece. During this time the epithelium is separated from the other intestinal 
layers. For lysis, 2.4 ml of RIPA buffer + PI (Complete EDTA-free Protease Inhibitor Cocktail tablets; Roche, 
Mannheim) is applied to the collected mouse tissue. To disrupt the epithelium a sonicator is used (4 pulses, lasting 
1 s each). Afterwards the lysate is incubated for 2 h at 4 °C on a rotator followed by centrifugation for 20 min at 
4 °C at 11700 rpm.
To obtain homogenate from cultures, cells were lysed and homogenized in lysis buffer (150 mM NaCl, 1% 
Triton X-100, 50 mM Tris–HCl, pH 8.0) containing protease inhibitor (Roche).
Protein concentration was determined by Bradford protein assay. Proteins were separated by SDS-PAGE and 
blotted onto nitrocellulose membranes (GE Healthcare). Immunoreactivity was visualized using horseradish per-
oxidase (HRP)-conjugated secondary antibodies and the SuperSignal detection system (Pierce).
For Co-Immunoprecipitation (Co-IP), enterocyte-like cells were washed and detached from the surface using 
a cell scraper and centrifuged at 3200 rpm. The pellet was lysed in 1.5 ml Triton X Lysis Buffer for 30 min on ice. 
Alternatively, protein lysate from mouse GI epithelium was used. Immunoprecipitation with 10 μ l SHANK3 anti-
body serum using μ MACS Columns and Protein G MicroBeads (Miltenyi Biotec) was performed according to 
the manufacturer’s protocol.
Statistic. Statistical analysis was performed using Graph Pad Prism 5 and tested for significance using t tests 
(all values were normally distributed). Two-Way ANOVA with Bonferroni correction was used to identify treat-
ment (Zn depletion/supplementation) or genotype effects, or interaction between the two factors using SPSS 
version 20. Statistical tests were two tailed with a significance level of α ≤ 0.05. Significances are stated with p 
values < 0.05*; < 0.01**; < 0.001***. An observed trend (p between 0.05 and 0.1) is indicated with “#” and the p 
value stated in the figures.
qRT PCR quantification. Relative quantification is based on internal reference genes to determine virtual mRNA 
levels of target genes. Cycle threshold (ct) values were calculated by the Rotor-Gene Q Software (version 2.0.2). 
Ct values were transformed into virtual mRNA levels according to the formula: virtual mRNA level = 10 * ((ct(tar-
get) − ct(standart))/slope of standard curve).
Western blot quantification. Evaluation of bands from Western blots (WBs) was performed using ImageJ. Three 
independent experiments were performed and blots imaged using a MicroChemi Imaging System from Biostep. 
The individual bands were selected and the integrated density was measured. All WB bands were normalized to 
β -Actin or GAPDH and the ratios averaged and tested for significance.
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